The European Commission (EC) has finalised an advance purchase agreement for up to 200 million doses of Novavax’s recombinant nanoparticle protein-based Covid-19 vaccine, NVX-CoV2373. The deal is for the acquisition of up to 100 million doses and an option for another 100 million doses through 2023. Novavax is currently progressing its rolling submission for the vaccine to the European Medicines Agency (EMA) in the third quarter of this year and the delivery of the first doses will start after approval.

The World Health Organization has called for a moratorium on Covid-19 vaccine boosters until the end of September at least, in a bid to boost vaccine supplies to low-income countries. The aim is to allow a minimum of 10% of each country’s population to be inoculated. WHO director-general Tedros Adhanom Ghebreyesus noted that high-income nations have administered nearly 100 doses for every 100 people so far while low-income nations only administered 1.5 doses for every 100 people due to a lack of supply.

NRx Pharmaceuticals has partnered with MannKind to develop a dry powder formulation of  Zyesami, which secured the US Food and Drug Administration’s fast track designation in acute lung injury or acute respiratory distress syndrome caused by Covid-19. In a Phase IIb/III trial, the drug was able to increase survival chances in Covid-19 patients with respiratory failure.